Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will participate in the ‘KIS Investors Conference 2026 Asia’ sponsored by Korea Investment & Securities in Hong Kong and Singapore to present its business status, key technologies, and R&D pipeline plans to foreign institutional investors.
📊 [Key Disclosure Details & Major Figures Summary]
- Event Name: KIS Investors Conference 2026 Asia Participation
- Date & Time: February 23, 2026 – February 25, 2026 (09:00 – 18:00, Local Time)
- Location: Hong Kong, Singapore
- Target Audience: Foreign institutional investors
- Purpose: To enhance corporate value by improving investor understanding of the company and key business visions
- Method: Participation in the conference hosted by Korea Investment & Securities (IR presentation & Q&A)
- Key Details: Introduction of company & key technologies, R&D pipeline status & future plans, Q&A
- Sponsoring Institution: Korea Investment & Securities
- Confirmation Date: February 20, 2026
- Contact Department: IR Team (Tel: +82-42-384-8777)
- IR Material Publication: Scheduled for publication on February 23, 2026, on the KRX KIND system website (http://kind.krx.co.kr)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Key Technologies and R&D Pipeline Updates via Published IR Materials
The company plans to publish its IR presentation materials on the KRX KIND system on February 23, 2026, for this event. Reviewing the official presentation materials provided to foreign institutional investors is essential because it allows investors to accurately understand the development progress of key technologies and R&D pipeline strategic directions. Detailed contents can be cross-checked in the official IR presentation materials published on the KRX KIND system website.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
